单唾液酸四己糖神经节苷脂治疗帕金森病的疗效和安全性的Meta分析

发布时间：2018-07-08 18:46

本文选题：GM1神经节苷酯 + 帕金森氏病　；参考：《广西医科大学》2014年硕士论文

【摘要】：目的应用Meta分析的方法综合评价单唾液酸四己糖神经节苷脂(GM1神经节苷酯)治疗帕金森氏病的有效性及安全性。方法通过计算机检索Medline数据库、Embase数据库(1976年—2014年3月)、Cochrane图书馆、中国生物医学文献数据库(CBM)(1980年—2014年3月)、web of science(1960年—2014年3月)、万方数据库(1994年—2014年3月)、维普资讯网(1991年—2014年3月)、相关期刊论文(1996年—2014年3月),纳入GM1神经节苷脂治疗帕金森氏病的随机对照研究(randomized controlled trial, RCT),采取Cochrane协作网提供的RevMan5.2的质量评价标准对纳入研究进行质量评价,提取纳入研究的有效性指标：治疗前后UPDRS (帕金森病统一评分量表)评分的均数和标准差；安全性指标：不良反应事件出现的人数。采用Cochrane协作网提供的RevMan5.2统计软件进行统计分析。根据异质性检验本研究的统计效应量疗效及注射部位相关不良事件的Meta分析应用固定效应模型。最后进行敏感性分析：检验Meta分析结果的稳定性。结果共纳入2个RCT,共125例患者。Meta分析结果显示GM1对比安慰剂治疗帕金森氏病UPDRS运动功能评分的改善[MD=-5.44,95%CI=(-5.94,-4.91),P0.000001],引起注射部位相关风险[RR=3.12,95%CI=[1.96,4.78],P0.00001]。这两方面其差异均具有统计学意义。结论GM1对于改善帕金森病患者的运动功能有效,治疗过程中不良反应轻微。由于纳入的实验研究较少,且存在一些缺陷,因此本研究结果有一定的不确定性,这些结论还有待多中心随机双盲实验进一步证实。
[Abstract]:Objective to evaluate the efficacy and safety of monosialic tetrahexose ganglioside (GM1) in the treatment of Parkinson's disease by meta-analysis. Methods the Medline database, Embase database (1976-March 2014), was searched by computer for the Cochrane Library. China Biomedical Literature Database (CBM) (1980-March 2014), Wanfang Database (1994-March 2014), WebNet (1991-March 2014), full text Database of Chinese Journals (1996-March 2014) , a randomized controlled study of GM1 ganglioside in the treatment of Parkinson's disease (randomized controlled trial, RCT), using the quality evaluation criteria provided by Cochrane collaboration, Revman 5.2, to evaluate the quality of the inclusion study. The validity indexes were extracted: the mean and standard deviation of UPDRS score before and after treatment, and the safety index: the number of adverse reaction events. The statistical analysis was carried out with Revman 5.2 software provided by Cochrane Cooperative Network. A fixed effect model was used for meta-analysis of statistical effects and adverse events related to injection site according to heterogeneity test. Finally, sensitivity analysis was performed to test the stability of Meta-analysis results. Results two RCTs were included, 125 patients. Meta-analysis results showed that GM1 compared with placebo on the improvement of UPDRS motor function score in Parkinson's disease [MD-5.495 CI = (-5.94 -4.91) P 0.000001], and caused the risk of injection site [RR3.1295CI= [1.964.78] P0.00001]. The difference between these two aspects is statistically significant. Conclusion GM1 is effective in improving motor function in patients with Parkinson's disease. Due to the small number of experimental studies and some defects, the results of this study are uncertain, and these conclusions need to be further confirmed by multi-center randomized double-blind experiments.
【学位授予单位】：广西医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R742.5

【参考文献】